Goldfinch’s phase 2 kidney disease therapy scores in one indication, misses in anothernews2022-02-28T07:20:35+00:00February 28th, 2022|FierceBiotech|
Biohaven to take a chance on Bristol Myers’ once-failed DMD mednews2022-02-25T15:50:24+00:00February 25th, 2022|FierceBiotech|
MacroGenics switches horses in CD123 race, canning flotetuzumab in favor of next-gen successornews2022-02-25T11:39:30+00:00February 25th, 2022|FierceBiotech|
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to marketnews2022-02-25T10:49:44+00:00February 25th, 2022|FierceBiotech|
Russian invasion of Ukraine could affect more than 200 clinical trials across biotech and pharmanews2022-02-24T19:51:33+00:00February 24th, 2022|FierceBiotech|
UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasionnews2022-02-24T19:51:33+00:00February 24th, 2022|FierceBiotech|
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020news2022-02-24T17:46:27+00:00February 24th, 2022|FierceBiotech|
Chutes & Ladders—A new Spark, in CEO form, at Roche’s gene therapy biotechnews2022-02-24T16:45:52+00:00February 24th, 2022|FierceBiotech|
Takeda, Arch back hC Bioscience with $24M for transfer RNAs, following Flagship into the fieldnews2022-02-24T16:01:26+00:00February 24th, 2022|FierceBiotech|
Orphazyme goes soul searching as EU advisers add 2nd rejection for rare disease drugnews2022-02-24T14:28:40+00:00February 24th, 2022|FierceBiotech|
